Grifols Secures FDA Approval for FESILTY Fibrinogen Concentrate for Congenital Fibrinogen Deficiency
I'm PortAI, I can summarize articles.
Grifols SA has received FDA approval for its FESILTY fibrinogen concentrate to treat congenital fibrinogen deficiency. Developed by Biotest, the product will be available in the US by mid-2026, expanding Grifols' bleeding management therapies portfolio. The original content was published by Grifols SA on December 19, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments